top of page



Oxalo Therapeutics is developing first-in-class therapeutics to treat rare renal diseases and prevent recurrent kidney stones 

starting with an orphan disease

primary hyperoxaluria

Genetics icon.png

Primary hyperoxaluria is a monogenic autosomal recessive liver disease that results in excessive endogenous oxalate.

kidneys icon.png

Extreme levels of oxalate lead to recurrent kidney stone formation, nephrocalcinosis and end stage renal disease very early in life.

Tablets icon.png

There are currently no effective therapies for this ultra rare disease, which affects an estimated 5,000 patients in the U.S. and E.U.

Oxalo Therapeutics is tackling primary hyperoxaluria and other oxalate pathologies


bacteria icon.png
bacteria icon.png
bacteria icon.png

The gut microbe Oxalobacter formigenes works together with the large intestine to maintain oxalate homeostasis.

Oxalo Therapeutics is isolating this powerful mechanism and replicating it through a first-in-class peptide therapeutic.


At Oxalo, we are committed to developing innovative therapies for patients with severe and rare kidney diseases caused by oxalate.
Oxalo Therapeutics, Inc.
Polsky Exchange
1452 E. 53rd St, 2nd Floor
Chicago, IL 60615
bottom of page